Hantech Bio-Technology Co., Ltd. (TPEX:1294)
Taiwan
· Delayed Price · Currency is TWD 79.40
-0.10 (-0.13%)
Apr 29, 2026, 1:30 PM CST
Hantech Bio-Technology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 778.54 | 748.42 | 625.14 | 302.52 | 240.29 | Upgrade
|
| Revenue Growth (YoY) | 4.02% | 19.72% | 106.65% | 25.90% | -9.90% | Upgrade
|
| Cost of Revenue | 489.65 | 442.68 | 344.29 | 175.89 | 139.27 | Upgrade
|
| Gross Profit | 288.9 | 305.74 | 280.85 | 126.63 | 101.03 | Upgrade
|
| Selling, General & Admin | 103.16 | 98.17 | 88.34 | 61.11 | 55.51 | Upgrade
|
| Research & Development | 12.18 | 10.13 | 7.37 | 8.09 | 6.9 | Upgrade
|
| Operating Expenses | 115.91 | 108.28 | 95.15 | 69.8 | 61.36 | Upgrade
|
| Operating Income | 172.98 | 197.47 | 185.71 | 56.84 | 39.67 | Upgrade
|
| Interest Expense | -2.98 | -5.38 | -2.12 | -1.47 | -1.55 | Upgrade
|
| Interest & Investment Income | 3.28 | 1.39 | 0.65 | 0.27 | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.55 | -0.03 | 2.57 | -0.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.27 | 0.96 | 0.46 | 0.07 | 0.45 | Upgrade
|
| EBT Excluding Unusual Items | 173.01 | 194.99 | 184.68 | 58.28 | 38.42 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.35 | -0.11 | -0.55 | -0 | Upgrade
|
| Pretax Income | 173.01 | 194.64 | 184.57 | 57.73 | 38.42 | Upgrade
|
| Income Tax Expense | 33.93 | 39.22 | 37.04 | 11.87 | 7.33 | Upgrade
|
| Earnings From Continuing Operations | 139.08 | 155.42 | 147.53 | 45.86 | 31.09 | Upgrade
|
| Minority Interest in Earnings | -0.03 | 0.26 | 0.59 | 1.61 | 1.47 | Upgrade
|
| Net Income | 139.05 | 155.67 | 148.12 | 47.47 | 32.56 | Upgrade
|
| Net Income to Common | 139.05 | 155.67 | 148.12 | 47.47 | 32.56 | Upgrade
|
| Net Income Growth | -10.68% | 5.10% | 212.00% | 45.81% | -41.62% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 28 | 28 | 26 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 29 | 28 | 26 | 24 | Upgrade
|
| Shares Change (YoY) | 4.66% | 3.38% | 8.45% | 7.98% | 2.60% | Upgrade
|
| EPS (Basic) | 4.60 | 5.47 | 5.36 | 1.86 | 1.41 | Upgrade
|
| EPS (Diluted) | 4.54 | 5.32 | 5.23 | 1.82 | 1.35 | Upgrade
|
| EPS Growth | -14.71% | 1.74% | 188.00% | 34.69% | -43.04% | Upgrade
|
| Free Cash Flow | 145.19 | 126.13 | -102.03 | -19.7 | -34.87 | Upgrade
|
| Free Cash Flow Per Share | 4.74 | 4.31 | -3.60 | -0.76 | -1.44 | Upgrade
|
| Dividend Per Share | - | 2.907 | 0.699 | 0.608 | - | Upgrade
|
| Dividend Growth | - | 315.99% | 14.99% | - | - | Upgrade
|
| Gross Margin | 37.11% | 40.85% | 44.93% | 41.86% | 42.04% | Upgrade
|
| Operating Margin | 22.22% | 26.38% | 29.71% | 18.79% | 16.51% | Upgrade
|
| Profit Margin | 17.86% | 20.80% | 23.69% | 15.69% | 13.55% | Upgrade
|
| Free Cash Flow Margin | 18.65% | 16.85% | -16.32% | -6.51% | -14.51% | Upgrade
|
| EBITDA | 211.15 | 221.24 | 198.27 | 68.54 | 50.96 | Upgrade
|
| EBITDA Margin | 27.12% | 29.56% | 31.72% | 22.66% | 21.21% | Upgrade
|
| D&A For EBITDA | 38.17 | 23.77 | 12.56 | 11.71 | 11.29 | Upgrade
|
| EBIT | 172.98 | 197.47 | 185.71 | 56.84 | 39.67 | Upgrade
|
| EBIT Margin | 22.22% | 26.38% | 29.71% | 18.79% | 16.51% | Upgrade
|
| Effective Tax Rate | 19.61% | 20.15% | 20.07% | 20.56% | 19.09% | Upgrade
|
| Revenue as Reported | 778.54 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.